Zambon S.p.A.

Q: What industry does Zambon S.p.A. belong to?

Zambon S.p.A. is in the industry of: Manufacturing , Pharmaceuticals

Manufacturing · Italy · 501-1,000 Employees

View Company Info for Free

Overview

Headquarters

Via Lillo Del Duca 10, Bresso, Lombardy,...

Phone Number

+49 301202120

Website

www.zambon.com

Revenue

$703.5 Million

Industry

Manufacturing

Pharmaceuticals

ZI Rank: 1

Signal Type

Dec

Jan

Feb

Mar

Apr

May

ZI Rank

Zambon S.p.A.’s Company Summary

Zambon S.p.A. is an established Italian multinational pharmaceutical company, founded in 1906. Specializing in the manufacturing of pharmaceuticals and biopharmaceuticals, the company operates within the broader healthcare sector. With a rich history spanning over a century, Zambon has dedicated itself to advancing patient care through innovation and the development of therapeutic solutions. Its core mission revolves around improving quality of life by addressing various diseases, including rare conditions, through rigorous research and development. The company's commitment to ethical practices and high-quality standards underpins its operations.

Operating across 5 locations, Zambon S.p.A. employs between 500 and 1,000 professionals. The company generated a revenue of $703.5M, reflecting its significant market presence and operational scale. This global footprint allows Zambon to distribute its pharmaceutical products effectively and engage in international collaborations. To understand the human capital driving these advancements, one can Meet Zambon S.p.A.'s team, gaining insight into the expertise and dedication of its workforce. The company's strategic approach integrates scientific discovery with manufacturing excellence to deliver impactful medical treatments.

Zambon's product portfolio encompasses a range of pharmaceutical and chemical compounds designed for patient use. The company actively pursues innovation in therapeutic areas, focusing on developing effective treatments and cures. Its biopharmaceutical endeavors highlight a forward-looking strategy aimed at tackling complex health challenges. Zambon's long-standing presence in the industry is a testament to its adaptability and enduring commitment to scientific progress and patient well-being. The company's focus on ethical pharmaceutical development ensures that its innovations meet stringent regulatory and quality benchmarks, contributing to global healthView more...

AI for GTM

The summary is generated by AI and may contain inaccuracies. Verify critical information with official sources.

About Zambon S.p.A.

Zambon, headquartered in Bresso, Lombardy, Italy, is a company that specializes in the manufacturing of pharmaceuticals.Explore more

Is this data correct?

View contact profiles from Zambon S.p.A.

Popular SearchesZambon SpaZambonZambon CoZambon GmbHZambon Services IncSIC Code 28,283NAICS Code 32,325Show more

Zambon S.p.A. Org Chart

Phone

Elena Rusakova

Financial Controller

Phone

Get the full picture

Is Zambon S.p.A. your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Check if Zambon S.p.A. has recently received funding, and reach out quickly before it becomes old news!

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Earning: See what the market has to say on Zambon S.p.A. recently announced quarterly report

Click to see if Zambon S.p.A. had a recent Job posting/layoffs

Check out if Zambon S.p.A. is spiking on competitors!

Website visits: Recent activity has been detected on your website

Funding: Get notified immidiatlly once Zambon S.p.A. has new funding data

Zambon S.p.A., which may be a good buyer, showed buying intent in Masked Content Topic

Product Launch: Get notified when Zambon S.p.A. launches new products

Congratulate Masked Content for being promoted to Masked Content at Zambon S.p.A.

Recommended Actions

Introduce yourself to Masked Content, who has shown a strong intent to purchase lately

Find 2 more new buyers

View Email Formats for Zambon S.p.A.

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Zambon S.p.A. is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Zambon S.p.A. is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zambon S.p.A..

Zambon S.p.A. Tech Stack

A closer look at the technologies used by Zambon S.p.A.

See more technologies

Most Recent Scoops

Hiring Plans

Zambon S.p.A. has more open roles in Marketing than it has had at any time in the past 6 months.

Hiring Plans

Project

Zambon S.p.A. is sponsoring an interventional clinical trial focused on extension trial of L-CsA + SoC efficacy and safety in post-transplant BOS. The trial began on March 2020 with the expected completion date of February 2026. The trial is currently in phase three.

Laboratory Operations, Medical Research, Clinical Operations

Hiring Plans

Zambon S.p.A. has more open roles in Operations than it has had at any time in the past 12 months.

Hiring Plans

Zambon S.p.A. has more open roles in Information Technology than it has had at any time in the past 12 months.

Hiring Plans

See more scoops

Zambon S.p.A. News & Media

Zambon Taps Kinaxis to Enhance Transparency Across Global Supply Chain
OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced Zambon, a multinational pharmaceutical company committed to innovating cure and care to make patients’ lives better, has selected Kinaxis to help orchestrate full visibility and transparency across its vast global supply chain. With 23 subsidiaries, a product presence in 87 countries and manufacturing facilities spread across three continents, the complexity of th
www.businesswire.com
Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa
Inhalation of colistimethate sodium via the I-neb® Adaptive Aerosol Delivery System (CMS I-neb) significantly reduced pulmonary exacerbations and improved quality of life in non-cystic fibrosis bronchiectasis (NCFB) patients colonized with P. aeruginosa Both trials showed that CMS I-neb...
www.prnewswire.com
Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
MILAN and BOSTON, May 12, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, today announced that the Company will attend the American Thoracic Society (ATS) 2022 Annual...
www.prnewswire.com
Zambon to present data on lung transplantation trends and survival rates in Europe at ISHLT 2022
Data suggest Bronchiolitis Obliterans Syndrome (BOS) accounts for two-thirds of Chronic Lung Allograft Dysfunction (CLAD) deaths, underscoring need for new treatments to address primary cause of death following lung transplantation Systematic review of lung transplant data uncovers a...
www.prnewswire.com
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
CMS I-neb® is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic, progressive, and irreversible respiratory disease Breakthrough designation validates registrational path...
www.prnewswire.com